Express Mail Label No. EJ7702 Date of Deposit: October 28, 1999

Please type a plus sign (+) in this box




D/643 Pulattachs

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	09/314,698
TRANSMITTAL FORM	Filing Date	09/314,698 May 19, 1999
(to be used for all correspondence after initial filing)	First Named Inventor	Perrin Poly
	Group Art Unit	1643
	Examiner Name	Not Assigned
	Attorney Docket Number	14791-501 (Ariad-1)
	ENCLOSURES (check all that a	apply)
Fee Transmittal Form	Assignment Papers (for an Application)	After-Allowance Communication to Group
Fee Attached	Drawing(s)	Appeal Communication to Board of Appeals and Interferences
Amendment/ Response	Petition Routing Ship (PTO/S and Accompanying Petition	Appeal Communication to Group (Brief, Reply Brief)
Affidavit(s)/Declaration(s)	To Convert a Provisional App	plication Proprietary Information
After Final	Combined Declaration and Power of Attorney	Licensing-related Papers
Notice of Appeal	Information Disclosure State	ment Certified Copy of Priority Document(s)
Extension of Time Request	Form 1449 PTO	Status Letter
Postcard	Small Entity Statement	Terminal Disclaimer
Response to Missing Parts (Filing Date Granted)	Request for Refund	
Additional Enclosure(s) (please identify to	pelow):	
28 Cited References		
SIGNATU	RE OF APPLICANT, ATTORNE	EY, OR AGENT
Submitted by	,	Registration No. 39,529
Signature	black	
Date October 28, 1999		

Express Mail Label No.: EJ 265397US

Date of Deposit: October 28, 1999



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Perrin et al.

ASSIGNEE:

Ariad Pharmaceuticals, Inc.

SERIAL NUMBER:

09/314,698

Not Assigned

FILING DATE:

May 19, 1999

ART UNIT:

1643

For:

MICROARRAY-BASED SUBTRACTIVE HYBRIDIZATION

October 28, 1999 Boston, Massachusetts

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent Documents:

Cite No.	U.S. Patent	Issue Date	Name of Applicant(s)	Class
A 1	5,445,934	08/29/95	Fodor, Stephen P.	6
A2	5,589,339	12/31/96	Hampson, Ian N.	6
A3	5,830,662	11/03/98	Soares, Marcelo B.	6
A4	5,846,721	12/08/98	Soares, Marcelo B.	6
A5	5,851,772	12/22/98	Mirzabekov, Andrei D.	6
A6	5,728,529	03/17/98	Metzker, Richard A.	6
A 7	5,800,992	09/01/98	Fodor, Stephen P.	6
A8	5,821,058	10/13/98	Smith, Lloyd M.	6
A9	5,882,874	03/16/99	Fisher, Paul B.	6

APPLICANTS: **U.S.S.N.:**

Perrin et al. 09/314,698

Foreign Patent Documents:

Cite	Foreign	Patent Document		
No.	Office	Number	Name of Patentee	Date of Publication
B1	WO	97/41260	Genescape, Inc.	6 November 1997
B2	WO	98/08973	Cancer Research Campaign Technology Ltd.	5 March 1998
B3	WO	98/43088	SmithKline Beecham Corporation	1 October 1998
B4	WO	99/15702	Life Technologies, Inc.	1 April 1999

Cite	Prior Art - Non Patent Literature Documents:
No.	Name of Author, Title, Publication, Volume, Page(s), Date, Etc.
C1	Adams, et al., SCIENCE, 252, 1651-1656 (1991).
C2	Boguski & Schuler, NAT. GENETICS. 10, 369-371 (1995).
C3	Botwell, D.L., NAT. GENETICS, 21, 25-29 (1999).
C4	Brown & Botstein, NAT. GENETICS, 21, 33-37 (1999).
C5	Dovichi, ELECTROPHORESIS, 18, 2393-2399 (1997).
C6	Duggan, et al., NAT. GENETICS, 21, 10-14 (1999).
C7	Ermolaeva, et al., NAT. GENETICS, 20, 19-23 (1998).
C8	Galau et al., ARCH. BIOCHEM BIOPHYS, 179, 584-599 (1977).
C9	Hacia, J.G., NAT. GENETICS, 21, 42-47 (1999).
C10	Ko, NUCLEIC ACIDS RES., 18, 5705-5711 (1990).
C11	Lipshutz, et al. NAT. GENETICS, 21, 20-24 (1999).
C12	Luckey et al., NUCLEIC ACIDS RES., 18, 4417-4421 (1990).
C13	Prober, et al., SCIENCE, 238, 336-341 (1987).
C14	Smith, et al., NATURE, 321, 674-679 (1986).
C15	Weissman, Mol. Biol. Med., 4, 133-143 (1987).

This Information Disclosure Statement is being been filed:

	within three months of the filing date of the National Application;
	within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
\boxtimes	before the mailing date of a first Office Action on the merits in the above-identified case
Accord	lingly, no fee or certification is required. 37 C.F.R. §1.97

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a

APPLICANTS: U.S.S.N.:

Perrin et al. 09/314,698

determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 14791-501.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

Heidi A. Erlacher, Technology Specialist

c/o MINTZ, LEVIN

One Financial Center Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: October 28, 1999

TRADOCS:1256800.1(QXR401!.DOC)